StreetInsider.com News Articles

Form SCHEDULE 13G/A BeyondSpring Inc. Filed by: Huang Lan

Tue, 17 Feb 2026 16:34:00 -0500

si-local-file:///var/storage/secattach/20260217/26013958.html

Form SCHEDULE 13G/A BeyondSpring Inc. Filed by: Huang Lan

Tue, 17 Feb 2026 16:34:00 -0500

si-local-file:///var/storage/secattach/20260217/26013958.html

Form SCHEDULE 13G/A BeyondSpring Inc. Filed by: Decheng Capital Management III (Cayman), LLC

Fri, 13 Feb 2026 16:29:00 -0500

si-local-file:///var/storage/secattach/20260213/26000861.html

Form SCHEDULE 13G/A BeyondSpring Inc. Filed by: Decheng Capital Management III (Cayman), LLC

Fri, 13 Feb 2026 16:29:00 -0500

si-local-file:///var/storage/secattach/20260213/26000861.html

BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference

Mon, 09 Feb 2026 07:15:00 -0500

FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced that the Company will participate in the Immuno-Oncology 360° (IO360°) Conference 2026, held February 10-12, 2026 in Boston, MA.

Dr. Lan Huang, Co-Founder, Chairman, and CEO of BeyondSpring, will present on Plinabulin as a differentiated immuno-oncology asset designed to enhance PD-1/PD-LD blockade and highlight Plinabulin’s unique mechanism of action and clinical development strategy.

Presentation Details:
Title: Overcoming PD-1/L1 Resistance: Translational Insights with Plinabulin
Track Number: 1. Translational Science

BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference

Mon, 09 Feb 2026 07:15:00 -0500

Presentation Details:
Title: Overcoming PD-1/L1 Resistance: Translational Insights with Plinabulin
Track Number: 1. Translational Science

BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference

Mon, 09 Feb 2026 07:15:00 -0500

Presentation Details:
Title: Overcoming PD-1/L1 Resistance: Translational Insights with Plinabulin
Track Number: 1. Translational Science

BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference

Mon, 09 Feb 2026 07:15:00 -0500

Presentation Details:
Title: Overcoming PD-1/L1 Resistance: Translational Insights with Plinabulin
Track Number: 1. Translational Science

Form 8-K BeyondSpring Inc. For: Dec 15

Mon, 15 Dec 2025 16:30:00 -0500

si-local-file:///var/storage/secattach/20251215/25741165.html

Form 8-K BeyondSpring Inc. For: Dec 15

Mon, 15 Dec 2025 16:30:00 -0500

si-local-file:///var/storage/secattach/20251215/25741165.html

BeyondSpring presents positive Asian subset data for lung cancer treatment

Fri, 12 Dec 2025 07:00:34 -0500

BeyondSpring Inc. (NASDAQ: BYSI) announced results from an Asian subset analysis of its Phase 3 DUBLIN-3 trial evaluating plinabulin plus docetaxel versus docetaxel alone in patients with EGFR wild-type non-small cell lung cancer. The data was presented at the European Society for Medical Oncology Asia Congress 2025.

The Asian subset included 488 patients from the global trial. The combination of plinabulin plus docetaxel achieved a median overall survival of 10.8 months compared to 8.8 months for docetaxel alone, with a hazard ratio of 0.81 and statistical significance at p=0.0426.

In the non-squamous patient subgroup, the hazard ratio was 0.69 with a median

BeyondSpring presents positive Asian subset data for lung cancer treatment

Fri, 12 Dec 2025 07:00:34 -0500

In the non-squamous patient subgroup, the hazard ratio was 0.69 with a median

BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a

Fri, 12 Dec 2025 07:00:00 -0500

Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement in 2L/3L EGFR WT NSCLC.

FLORHAM PARK, N.J., Dec. 12, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced results from the Asian subset (n=488) of its global Phase 3 DUBLIN-3 trial evaluating Plinabulin plus docetaxel compared to docetaxel alone in second- or third-line EGFR wild-type non-small cell lung cancer (NSCLC). Dublin-3’s global

BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a

Fri, 12 Dec 2025 07:00:00 -0500

Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement in 2L/3L EGFR WT NSCLC.

BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a

Fri, 12 Dec 2025 07:00:00 -0500

Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement in 2L/3L EGFR WT NSCLC.

BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a

Fri, 12 Dec 2025 07:00:00 -0500

Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement in 2L/3L EGFR WT NSCLC.

BeyondSpring reports survival benefit in lung cancer study analysis

Thu, 11 Dec 2025 07:02:13 -0500

BeyondSpring Inc. (NASDAQ: BYSI) announced new analyses from its DUBLIN-3 Phase 3 study showing that plinabulin combined with docetaxel improved survival outcomes in patients with non-squamous EGFR wild-type non-small cell lung cancer who had progressed after anti-PD-(L)1 immunotherapy.

The post-hoc analysis presented at the 2025 North America Conference on Lung Cancer showed median overall survival of 15.8 months for the plinabulin plus docetaxel combination compared to 11.7 months for docetaxel alone. Median progression-free survival was 5.6 months versus 3.8 months, and objective response rate was 18.2% versus 8.0%.

The analysis included patients who had at least three months of prior clinical benefit

BeyondSpring reports survival benefit in lung cancer study analysis

Thu, 11 Dec 2025 07:02:13 -0500

The analysis included patients who had at least three months of prior clinical benefit

BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis

Thu, 11 Dec 2025 07:00:00 -0500

In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin as a late-stage therapy with consistent survival benefit in anti-PD-(L)1-progressed NSCLC patients.
Supported by anti-cancer efficacy and safety in significant reduction exposure-adjusted grade 3/4 adverse events in DUBLIN-3, BeyondSpring will conduct DUBLIN-4, a global, double-blind Phase 3 registrational trial. This study will evaluate Plinabulin + docetaxel vs. docetaxel in non-squamous EGFR wild-type NSCLC after progression on anti-PD-(L)1 and chemotherapy, and is intended to serve as the global confirmatory

BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis

Thu, 11 Dec 2025 07:00:00 -0500

In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin as a late-stage therapy with consistent survival benefit in anti-PD-(L)1-progressed NSCLC patients.
Supported by anti-cancer efficacy and safety in significant reduction exposure-adjusted grade 3/4 adverse events in DUBLIN-3, BeyondSpring will conduct DUBLIN-4, a global, double-blind Phase 3 registrational trial. This study will evaluate Plinabulin + docetaxel vs. docetaxel in non-squamous EGFR wild-type NSCLC after progression on anti-PD-(L)1 and chemotherapy, and is intended to serve as the global confirmatory

BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis

Thu, 11 Dec 2025 07:00:00 -0500

In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin as a late-stage therapy with consistent survival benefit in anti-PD-(L)1-progressed NSCLC patients.
Supported by anti-cancer efficacy and safety in significant reduction exposure-adjusted grade 3/4 adverse events in DUBLIN-3, BeyondSpring will conduct DUBLIN-4, a global, double-blind Phase 3 registrational trial. This study will evaluate Plinabulin + docetaxel vs. docetaxel in non-squamous EGFR wild-type NSCLC after progression on anti-PD-(L)1 and chemotherapy, and is intended to serve as the global confirmatory

BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis

Thu, 11 Dec 2025 07:00:00 -0500

In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin as a late-stage therapy with consistent survival benefit in anti-PD-(L)1-progressed NSCLC patients.
Supported by anti-cancer efficacy and safety in significant reduction exposure-adjusted grade 3/4 adverse events in DUBLIN-3, BeyondSpring will conduct DUBLIN-4, a global, double-blind Phase 3 registrational trial. This study will evaluate Plinabulin + docetaxel vs. docetaxel in non-squamous EGFR wild-type NSCLC after progression on anti-PD-(L)1 and chemotherapy, and is intended to serve as the global confirmatory

Form 8-K BeyondSpring Inc. For: Nov 17

Fri, 21 Nov 2025 16:30:00 -0500
si-local-file:///var/storage/secattach/20251121/25650039.html

Form 8-K BeyondSpring Inc. For: Nov 17

Fri, 21 Nov 2025 16:30:00 -0500
si-local-file:///var/storage/secattach/20251121/25650039.html

Form 424B5 BeyondSpring Inc.

Mon, 17 Nov 2025 16:31:00 -0500
si-local-file:///var/storage/secattach/20251117/25625615.html